The expanded development and application of CRISPR system for sensitive nucleotide detection

Jia, Fengjing; Li, Xuewen; Zhang, Chao; Tang, Xueming

doi:10.1007/s13238-020-00708-8

Cited by 32 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Post-perusal of the literature, cited in this article, one may easily perceive the prospects of employing CRISPR technology to address the viral assault as well as improve testing speed in the context of global paucity of timely COVID-19 tests. As far as the use of CRISPR technology for viral detection is concerned, researchers must address plausible off-target effects of CRISPR which might hinder the precise nucleotide detection ( Jia et al, 2020 ). The accuracy may also be affected as CRISPR/Cas effectors tend to show some sort of tolerance to mismatches between the guide RNA and target nucleotides.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Pertinently, exploiting CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated) systems ( Makarova et al, 2020 ) for sensitive nucleotide detection has been an interesting endeavor in recent years ( Jia et al, 2020 ). Resorting to CRISPR/Cas systems for the diagnosis as well as inactivation of RNA and DNA viruses has opened up new portals in clinical virology ( Jia et al, 2020 ). These systems employ platforms like specific high sensitivity enzymatic reporter unlocking or SHERLOCK ( Gootenberg et al, 2017 ), DNA endonuclease-targeted CRISPR trans reporter or DETECTR ( Chen et al, 2018 ), 1-h low-cost multipurpose highly efficient system or HOLMES ( Li et al, 2019 ) and Cas13-assisted restriction of viral expression and readout or CARVER ( Freije et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Konwarh

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

The current global debacle of COVID-19, spelled by SARS-CoV-2 needs no elaboration. With incessant and constantly clambering number of deaths across various nations, the need of the hour is to develop readily deployable, fast, affordable detection assays and kits, yielding precise and consistent results as well as timely availability of efficacious anti-SARS-CoV-2 strategies to contain it. Conventionally employed real time PCR based technique for detection of the virus suffers from a couple of handicaps. Amongst other approaches, CRISPR based technology has ushered in new hopes. Recent efforts have been directed toward developing CRISPR/Cas based low-cost, rapid detection methods as well as development of one-pot assay platforms. The plausible application of CRISPR-Cas system to counteract the viral assault has also been assessed. The write up in this article mirrors the current status, the prospects and the practical snags of CRISPR/Cas technology for the detection and inactivation of the novel corona virus, SARS-CoV-2.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Konwarh

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…CRISPR-Cas systems have shown their potential to be utilized as molecular diagnostics for detecting nucleic acids (Pardee et al, 2016;Jia et al, 2020) and may replace PCR in many applications. CRISPR-Cas-based diagnostic tools are characterized by sensitivity and specificity comparable to those of traditional PCR, but since they do not require sophisticated, and therefore, expensive equipment, they are associated with meager estimated costs.…”

Section: Crispr-based Applications For Covid-19 Diagnosismentioning

confidence: 99%

“…CRISPR-Cas system has been identified as a part of adaptive immune system in archaea and bacteria against the virus infections (Brouns et al, 2008) and its applications in humans were found later (Jinek et al, 2012). This system is a promising tool to develop novel diagnostics and also for development of therapeutics to eliminate viral infections (Bayat et al, 2018;Jia et al, 2020). A novel antiviral therapy for treating HIV patients has been developed using the CRISPR-Cas technology (Huang et al, 2017;Herrera-Carrillo et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics

Kumar

Malik

Ganesh

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

COVID-19, the human coronavirus disease caused by SARS-CoV-2, was reported for the first time in Wuhan, China in late 2019. COVID-19 has no preventive vaccine or proven standard pharmacological treatment, and consequently, the outbreak swiftly became a pandemic affecting more than 215 countries around the world. For the diagnosis of COVID-19, the only reliable diagnostics is a qPCR assay. Among other diagnostic tools, the CRISPR-Cas system is being investigated for rapid and specific diagnosis of COVID-19. The CRISPR-Cas-based methods diagnose the SARS-CoV-2 infections within an hour. Apart from its diagnostic ability, CRISPR-Cas system is also being assessed for antiviral therapy development; however, till date, no CRISPR-based therapy has been approved for human use. The Prophylactic Antiviral CRISPR in huMAN cells (PAC-MAN), which is Cas 13 based strategy, has been developed against coronavirus. Although this strategy has the potential to be developed as a therapeutic modality, it may face significant challenges for approval in human clinical trials. This review is focused on describing potential use and challenges of CRISPR-Cas based approaches for the development of rapid and accurate diagnostic technique and/or a possible therapeutic alternative for combating COVID-19. The assessment of potential risks associated with use of CRISPR will be important for future clinical advancements.

show abstract

CRISPR‐based point‐of‐care diagnostics incorporating Cas9, Cas12, and Cas13 enzymes advanced for SARS‐CoV‐2 detection

Verma

Roychowdhury

Sahu

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

An outbreak of the novel beta coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) first came to light in December 2019, which has unfolded rapidly and turned out to be a global pandemic. Early prognosis of viral contamination involves speedy intervention, disorder control, and good‐sized management of the spread of disease. Reverse transcription‐polymerase chain reaction, considered the gold standard test for detecting nucleic acids and pathogen diagnosis, provides high sensitivity and specificity. However, reliance on high‐priced equipped kits, associated reagents, and skilled personnel slow down sickness detection. Lately, the improvement of clustered regularly interspaced short palindromic repeat (CRISPR)‐Cas (CRISPR‐associated protein)‐based diagnostic systems has reshaped molecular diagnosis due to their low cost, simplicity, speed, efficiency, high sensitivity, specificity, and versatility, which is vital for accomplishing point‐of‐care diagnostics. We reviewed and summarized CRISPR–Cas‐based point‐of‐care diagnostic strategies and research in these paintings while highlighting their characteristics and challenges for identifying SARS‐CoV‐2.

show abstract

The expanded development and application of CRISPR system for sensitive nucleotide detection

Cited by 32 publications

References 38 publications

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches

CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics

CRISPR‐based point‐of‐care diagnostics incorporating Cas9, Cas12, and Cas13 enzymes advanced for SARS‐CoV‐2 detection

Contact Info

Product

Resources

About